Radiotherapy for Prostate Cancer: Hypofractionation of Radiation - Jason Efstathiou
In this edition of 5 for 5, Dr. Jason Efstathiou discusses the benefits of hypofractionation and the radiobiological potential for therapeutic gain in prostate cancer. Dr. Efstathiou reviews the NRG Oncology RTOG 0415, RTOG 0938 studies and the CHHiP Trial. Results from these trials and other moderate hypofractionation trials lead to conclusions that hypofractionation is safe and effective and has other potential advantages over standard fractionation.
Biography:
Biography:
Jason A. Efstathiou, MD, Phil
Associate Professor
Director, Genitourinary Division
Department of Radiation Oncology
Clinical Co-Director, Bertucci Center for GU Cancers
Massachusetts General Hospital
Harvard Medical School
Read more on Hypofractionation:
Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO)
Read more on Hypofractionation:
Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO)